PMID- 10202013 OWN - NLM STAT- MEDLINE DCOM- 19990506 LR - 20211203 IS - 0022-1767 (Print) IS - 0022-1767 (Linking) VI - 162 IP - 8 DP - 1999 Apr 15 TI - An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest. PG - 4720-30 AB - We have previously shown that CD40 causes strong activation of the c-Jun N-terminal kinase (JNK), the p38 mitogen-activated protein kinases (MAPK) and MAPKAP kinase-2, a downstream target of p38 MAPK. To identify signaling motifs in the CD40 cytoplasmic domain that are responsible for activation of these kinases, we have created a set of 11 chimeric receptors consisting of the extracellular and transmembrane domains of CD8 fused to portions of the murine CD40 cytoplasmic domain. These chimeric receptors were expressed in WEHI-231 B lymphoma cells. We found that amino acids 35-45 of the CD40 cytoplasmic domain constitute an independent signaling motif that is sufficient for activation of the JNK and p38 MAPK pathways, as well as for induction of I kappa B alpha phosphorylation and degradation. Amino acids 35-45 were also sufficient to protect WEHI-231 cells from anti-IgM-induced growth arrest. This is the same region of CD40 required for binding the TNF receptor-associated factor-2 (TRAF2), TRAF3, and TRAF5 adapter proteins. These data support the idea that one or more of these TRAF proteins couple CD40 to the kinase cascades that activate NF-kappa B, JNK, and p38 MAPK. FAU - Sutherland, C L AU - Sutherland CL AD - Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada. FAU - Krebs, D L AU - Krebs DL FAU - Gold, M R AU - Gold MR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Immunol JT - Journal of immunology (Baltimore, Md. : 1950) JID - 2985117R RN - 0 (Antibodies, Anti-Idiotypic) RN - 0 (CD40 Antigens) RN - 0 (CD8 Antigens) RN - 0 (CD8 receptor) RN - 0 (DNA-Binding Proteins) RN - 0 (I-kappa B Proteins) RN - 0 (Immunoglobulin M) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (NF-kappa B) RN - 0 (NFKBIA protein, human) RN - 0 (Nfkbia protein, mouse) RN - 0 (Peptide Fragments) RN - 0 (Proteins) RN - 0 (Receptors, Antigen, T-Cell) RN - 0 (Receptors, Tumor Necrosis Factor) RN - 0 (Recombinant Fusion Proteins) RN - 0 (TNF Receptor-Associated Factor 6) RN - 0 (anti-IgM) RN - 139874-52-5 (NF-KappaB Inhibitor alpha) RN - 2ZD004190S (Threonine) RN - EC 2.7.1.- (MAP-kinase-activated kinase 2) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases) RN - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) SB - IM MH - Amino Acid Sequence MH - Animals MH - Antibodies, Anti-Idiotypic/*physiology MH - Base Sequence MH - Binding Sites/immunology MH - CD40 Antigens/genetics/*physiology MH - CD8 Antigens/genetics MH - Calcium-Calmodulin-Dependent Protein Kinases/*metabolism MH - Cell Division/immunology MH - Cytoplasm/chemistry/enzymology/*immunology MH - DNA-Binding Proteins/*metabolism MH - Enzyme Activation/immunology MH - Humans MH - *I-kappa B Proteins MH - Immunoglobulin M/*immunology MH - Intracellular Signaling Peptides and Proteins MH - JNK Mitogen-Activated Protein Kinases MH - Mice MH - *Mitogen-Activated Protein Kinases MH - Molecular Sequence Data MH - NF-KappaB Inhibitor alpha MH - NF-kappa B/metabolism MH - Peptide Fragments/physiology MH - Peptide Mapping MH - Phosphorylation MH - Protein Serine-Threonine Kinases/*metabolism MH - Proteins/metabolism MH - Receptors, Antigen, T-Cell/biosynthesis/genetics MH - Receptors, Tumor Necrosis Factor/metabolism MH - Recombinant Fusion Proteins/biosynthesis/immunology MH - Signal Transduction/immunology MH - TNF Receptor-Associated Factor 6 MH - Threonine/physiology MH - Tumor Cells, Cultured EDAT- 1999/04/14 00:00 MHDA- 1999/04/14 00:01 CRDT- 1999/04/14 00:00 PHST- 1999/04/14 00:00 [pubmed] PHST- 1999/04/14 00:01 [medline] PHST- 1999/04/14 00:00 [entrez] PST - ppublish SO - J Immunol. 1999 Apr 15;162(8):4720-30.